MedTrace Logo

Betaferon® Regulatory Post-Marketing Surveillance

NCT01414816 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 355

Last updated 2014-08-21

No results posted yet for this study

Summary

To identify problems/questions about following items in the clinical practice using Betaferon

1. Unknown adverse event (especially serious adverse event)
2. Identification of adverse event occurred in the real practice
3. Factors that may affect the safety of drug
4. Factors that may affect the effectiveness of the drug

Conditions

Interventions

DRUG

Interferon beta-1b (Betaseron, BAY86-5046)

EOD, dosage frequency and duration will be decide by physicians.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • South Korea

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01414816 on ClinicalTrials.gov